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Letters to the Editor
Is Prolong Use of Statins
Associated With Increase
in the Risk of Diabetes?
The study by Wang et al. (1) assessed the risk of diabetes
associated with statin use in the general population. The authors
concluded that statin therapy is associated with an elevated risk for
diabetes. However, the study does not indicate the classes or
proportion of the different antihypertensive drugs (AHDs) admin-
istered in the statin-treated and control populations. This infor-
mation is imperative because thiazide diuretics and specific beta-
blockers exhibit undesirable glycemic effects.
Assessment of the ALLHAT study (Antihypertensive and
Lipid-Lowering Treatment to Prevent Heart Attack Trial) re-
vealed that the 4-year incidence of new-onset diabetes mellitus was
significantly elevated in the chlorthalidone group compared with
either the amlodipine or lisinopril group (11.6% vs. 9.8% and 8.1%,
respectively; p  0.05) (2). Comparable outcomes were also
obtained from the INSIGHT (International Nifedipine GITS
Study of Intervention as a Goal in Hypertension Treatment) and
ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial–
Blood Pressure Lowering Arm) trials (3,4). These effects of diuretic
AHDs on glucose metabolism are plausibly due to hypokalemia
induced by these drugs.
Hyperglycemia induced by beta-blockers is due to the reduction
in peripheral blood flow, followed by the channeling of blood away
from locales of glucose uptake, thereby reducing glucose clearance.
A systematic review by Elliott and Meyer (5), with 48 randomized
groups of 22 clinical trials involving 143,153 participants, revealed
that association of AHDs with incident diabetes is the highest for
beta-blockers and diuretics (in rank order).
Therefore, the question that remains unrequited in the current
study – “Is the adverse glycemic effect of statins observed in the
present study getting augmented, as a greater number of subjects in
the statin-group are being treated for hypertension with diuretics
or beta-blockers?”
Furthermore, a prospective population-based cohort study by
Dunder et al. (6) examined the impact of blood glucose elevationon the risk of developing myocardial infarction in individuals
between 50 and 60 years of age who were receiving AHDs. They
found that the elevated blood glucose and proinsulin levels
produced by use of diuretics and beta-blockers were linked to the
increased risk of myocardial infarction in these subjects. Therefore,
in the current study, if the statin-treated group has a higher
number of subjects receiving diuretics and beta-blockers, then the
favorable outcome of statins may be further augmented.
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Reply
We thank Dr. Banerjee for his comments regarding our publica-
tion on statin therapy and the risk of incident diabetes (1). He
highlighted for us the importance of diabetogenic effects of
concomitant medications, particularly diuretics and beta-blockers,
which have been independently associated with a higher risk of
diabetes (2,3).
The effects of diuretics and beta-blockers were essential in our
analysis because 73.9% of subjects in our population had hyper-
tension and 8.6% had heart failure. Our approach of matching
measurable comorbid risks to establish the study cohort resulted in
a similar distribution of demographic characteristics and cardio-
vascular comorbidities. There was no significant difference in the
proportions of diuretic and beta-blocker use among the control
group and the statin group (13.1% vs. 13.0%, p  0.795 [diuret-
ics]; 34.5% vs. 34.3%, p  0.693 [beta-blockers]). Statins, diuret-
ics, and beta-blockers were associated with an increase in risk of
incident diabetes; hazard ratios (95% confidence intervals) were
RR
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March 5, 2013:985–911.15 (1.08 to 1.22), 1.53 (1.42 to 1.64), and 1.40 (1.33 to 1.48),
respectively. In the multivariate model adjusted for age, sex,
comorbid risk, and concomitant diuretics and beta-blockers, statin
therapy was independently associated with the risk of diabetes
occurrence (hazard ratio: 1.13 [95% confidence interval: 1.07 to
1.20], p  0.001).
Statin therapy has been associated with excessive occurrence of
diabetes in subjects with unfavorable metabolic profiles (4,5).
Beyond that, it is particularly important to investigate whether the
risk would be further amplified by the concomitant treatment
targeting those factors to decide the treatment matrix for future
patients.
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Slimming the Heart
With Bariatric Surgery
We read with interest the paper by Gaborit et al. (1) describing the
effects of bariatric surgery on epicardial fat and myocardial triglyc-
eride content (MTGC). One of the authors’ main conclusions is
that a reduction in epicardial fat may be partially responsible for
the decrease in cardiac mortality observed after successful weight-
loss surgery because ectopic cardiac fat releases inflammatory
mediators and free fatty acids into the vasculature (1). The study
also demonstrates a decrease in systemic insulin resistance and
improvement in diastolic function after bariatric surgery. We have
made similar observations (2–4) and wish to offer a somewhat
different interpretation, which should complement the authors’
well-designed study. In patients with clinically severe obesity and
insulin resistance, we observed a negative association between the
plasma levels of long-chain free fatty acids and diastolic function
and suggest that excess free fatty acids exert lipotoxic effects on the
heart, leading to impairment in intracellular calcium cycling andcardiac function (2). Thus, one may reasonably conclude that the
improvement in cardiac function after bariatric surgery is directly
related to a decrease in lipotoxicity. However, no considerable
change in MTGC was appreciated in the authors’ study through
the use of magnetic resonance spectroscopy despite a statistically
significant decrease in epicardial fat and serum triglyceride levels.
One plausible explanation involves the modality used in the
measurement of MTGC. The practical method used to determine
MTGC is a conventional technique known as voxel positioning in
the ventricular septum to avoid contamination from epicardial fat
and lessen the degree of artifact from cardiac motion. Nonetheless,
the distribution of triglycerides in the human heart is heteroge-
neous in nature; thus, the conventional approach does not correlate
well with overall cardiac steatosis (5).
After successful bariatric surgery, our studies also show a
remarkable decrease in increased plasma free fatty acid levels, as
well as improved derangements in muscle metabolism and cardiac
function (3). Moreover, even as other hallmarks of obesity, such as
insulin resistance, free fatty acid levels, body composition, and
body mass index, have a tendency to plateau postoperatively, the
benefits of successful weight-loss surgery on left ventricular mass
are sustained and show a linear decrease over a 2-year period (4).
In short, our earlier work adds to the authors’ remarkable study
on the effects of weight loss after bariatric surgery on cardiac
function. We propose that by targeting the source of excess energy,
weight-loss surgery reduces left ventricular mass and improves
overall cardiac function by limiting the substrate supply to a
metabolically overloaded heart (6). The decrease in epicardial fat
volume after weight loss likely plays a key role in decreasing fatty
acid fuel to the heart, further reducing lipotoxicity. There is much
more to be gained from this fascinating area of research.
Khaled Imad Khalaf, MD
*Heinrich Taegtmeyer, MD, DPhil
*Department of Medicine/Cardiology
The University of Texas Medical School at Houston
University of Texas School of Medicine at Houston
6431 Fannin, MSB 1.246
Houston, Texas 77030
E-mail: Heinrich.Taegtmeyer@uth.tmc.edu
http://dx.doi.org/10.1016/j.jacc.2012.10.045
EFERENCES
1. Gaborit B, Jacquier A, Kober F, et al. Effects of bariatric surgery on
cardiac ectopic fat: lesser decrease in epicardial fat compared to visceral
fat loss and no change in myocardial triglyceride content. J Am Coll
Cardiol 2012;60:1381–9.
2. Leichman JG, Aguilar D, King TM, Vlada A, Reyes M, Taegtmeyer H.
Association of plasma free fatty acids and left ventricular diastolic
function in patients with clinically severe obesity. Am J Clin Nutr
2006;84:336–41.
3. Leichman JG, Wilson EB, Scarborough T, et al. Dramatic reversal of
derangements in muscle metabolism and diastolic left ventricular
function after bariatric surgery. Am J Med 2008;121:966–73.
4. Algahim MF, Lux TR, Leichman JG, et al. Progressive regression of
left ventricular hypertrophy two years after bariatric surgery: an unex-
pected dissociation with the body mass index. Am J Med 2010;123:
549–55.
5. Liu C, Redheuil1 A, Steenbergen C, et al. Measurement of myocardial
triglyceride content by magnetic resonance spectroscopy in transplant
native heart autopsies. J Cardivasc Mag Reson 2010;12 Suppl 1:P125.
